Specific immunotherapy in ovarian cancer: A systematic review

Soroush Alipour, Samaneh Zoghi, Nastaran Khalili, Armin Hirbod-Mobarakeh, Leisha A. Emens, Nima Rezaei

Research output: Contribution to journalReview articlepeer-review

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several approaches of active and passive immunotherapy for EOC have been studied. The aim of this systematic review was to assess the clinical efficacy of specific immunotherapy in patients with EOC. We found 4524 references in seven databases and we included ten controlled clinical trials with 2285 patients with EOC reporting five active immunotherapeutic agents and three passive immunotherapies. Meta-analysis of six studies showed that overall there was not any significant difference in overall survival and recurrence-free survival between patients undergoing specific immunotherapy and those in control group. Most of the studies we evaluated reported a positive outcome from treatment with specific immunotherapy, although this was not significant.

Original languageEnglish (US)
Pages (from-to)1193-1204
Number of pages12
JournalImmunotherapy
Volume8
Issue number10
DOIs
StatePublished - Oct 2016

Keywords

  • active immunotherapy
  • clinical outcome
  • immunotherapy
  • meta-analysis
  • ovarian cancer
  • passive immunotherapy
  • systematic review
  • vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Specific immunotherapy in ovarian cancer: A systematic review'. Together they form a unique fingerprint.

Cite this